

UTILITY PATENT APPLICATION TRANSMITTAL

(only for new non-provisional applications under 37 CFR §1.53(b))

Commissioner of Patents Box Patent Application Washington, D.C. 20231 Sir:

Transmitted herewith for filing is the patent application under 37 CFR 1.53(b) of:

AVENTIS DOCKET NO .: CA2295US NP

INVENTORS: Alan J. Collis et al

TITLE:

HETEROARYL-CYCLIC ACETALS

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail in an envelope addressed to Commissioner for Patents, Washington, D.C. 20231, on

PATEN

Date of Deposit 2 101

Signature

Express Mail No.

AP	PLICA	HON	ELEMENIS
1	\boxtimes	*Fee	Transmittal

*Fee Transmittal Form (e.g., PTO/SB/17)
(Submit an original and a duplicate for fee processing)

2. Specification

(preferred arrangement set forth below)

- Descriptive title of the Invention
- Cross References to Related Applications
- Statement Regarding Fed sponsored R & D
- Reference to Microfiche Appendix
- Background of the Invention
- Brief Summary of the Invention
- Brief Description of the Drawings (if filed)
- Detailed Description
- Claim(s)
- Abstract of the Disclosure

3.	 Drawing(s) (35 U.S.C.	113)

Total Sheets

Total Pages

0

55

4. Oath or Declaration

i.

a.

Newly unexecuted

Total Pages

2

b. Copy from a prior application (37 CFR § 1.63(d))

(for continuation/divisional with Box 16 completed)

DELETION OF INVENTOR(S)

Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR §§ 1.63(d)(2) and 1.33(b).

5. Microfiche Computer Program (Appendix)

6. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)

a. Computer Readable Copy

b. | Paper Copy (identical to computer copy)

c. Statement verifying identity of above copies

The state of the second control of the secon

	\boxtimes	If a CONTINUING Application, check appropriate box, and supply the requisite information:	
		Continuation Divisional Continuation-in-part	
		of prior application no: PCT /GB99/04283, filed December 16, 1999,	
		Examiner, Group/Art Unit (The cross reference has been/will be inserted on page one of the specification).	
		(The cross reference has been will be inserted on page one of the specification).	
	\boxtimes	This application claims the benefit of GB Application No. 9827721.3, filed	
		December 16, 1998, and U.S. Provisional Application No. 60/122,425,	
		filed March 2, 1999. (The cross reference has been/will be inserted on page one of the specification).	
		Incorporation By Reference (useable if filing a continuation/divisional and a copy of the declaration from the pro-	rior
		application is enclosed.) The entire disclosure of the prior application, from which a copy of the oath or declaration is	
		supplied, is considered as being part of the disclosure of the accompanying application and is	
		hereby incorporated by reference therein.	
	ACC	OMPANYING APPLICATION PARTS	
	7.00		
	7.	Assignment Papers (cover sheet & document(s))	
1	8.	37 CFR §3.73(b) Statement Power of	
	0	(when there is an assignee) Attorney	
LU Lu	9. 10.	English Translation Document (if applicable) Information Disclosure Copies of IDS	
	10.	Statement (IDS)/PTO-1449 Citations	
	11.	Preliminary Amendment	
	12.	Return Receipt Postcard (MPEP 503)	
33		(Should be specifically itemized)	
	13.	*Small Entity Statement(s) Statement filed in prior application, (PTO/SB/09-12) Status still proper and desired	
	14.	Certified Copy of Priority Document(s)	
pot pot		(if foreign priority is claimed)	
	15.	Other: EFS Print	
			
	COF	RESPONDENCE ADDRESS 005487	
	\boxtimes	Customer Number or Bar Code Label	
		(hand Contained blanch barried blanch)	
		(Insert Customer No or Attach bar code label here)	
		de Mar	
		rving Newman, Reg. No. 22,638	
	۸٠	Attorney/Agent for Applicant	
		ntis Pharmaceuticals Inc. nt Department	
		te #202-206 / P.O. Box 6800	

Mail Code: EMC-G1

Bridgewater, New Jersey 08807-0800 Telephone (908) 231-2785 Telefax (908) 231-2626

Aventis Docket No. CA2295US NP

Patent and Trademark Office. U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

FEE TRANSMITTAL for FY 2001

Patent fees are subject to annual revision.

TOTAL	AMOUNT	OF PAY	MENT	1

Signature

(\$) 710

C	Complete if Known			
Application Number	TBD			
Filing Date	Concurrently herewith			
First Named Inventor	Alan J. Collis et al			
Examiner Name	TBD			
Group / Art Unit	TBD			
Attorney Docket No.	CA2295US NP			

Date

METHOD OF PAYMENT	FEE CALCULATION (continued)							
1. The Commissioner is hereby authorized to charge			VAL FE					
indicated fees and credit any overpayments to:	1	Large		Small				
Deposit		Entity	_	Entity				
Account Number 18-1982	Fee Code	Fee (\$)	Fee Code	Fee (\$)		Fee Description	ı	Fee Paid
Deposit Account Name Aventis Pharmaceuticals Products Inc.	105	130	205	65		late filing fee or		
Charge Any Additional Fee Required	127	50	227	25	Surcharge - cover sheet	late provisional f	iling tee or	
Under 37 CFR 1.16 and 1.17 Applicant claims small entity status.	139	130	139	130		Specification		
See 37 CFR 1 27	147	2,520	147	2,520	For filing a r	equest for reexa	mination	
2. Payment Enclosed:	112	920*	112	920*	•	publication of SII		
Check Credit Card Money Order Other	' ''2	020			Examiner a	ction		
FEE CALCULATION	113	1,840*	113	1,840*	Requesting Examiner a	publication of SII ction	R after	
1. BASIC FILING FEE	115	110	215	55	Extension for	or reply within firs	t month	
Large Entity Small Entity	116	390	216	195		or reply within se		
Fee Fee Fee Fee Description Fee Gode (\$) Code (\$) Paid								
101 710 201 355 Utility filing fee 710	117	890	217	445		or reply within thi		
106 320 206 160 Design filing Fee	118	1,390	218	695		or reply within for		
07 490 207 245 Plant filing fee	128	1,890	228	945		or reply within fift	h month	
08 710 208 355 Reissue filing fee	119	310	219	155	Notice of A	•		
150 214 75 Provisional filing fee	120	310	220	155	Filing a brie	ef in support of ar	appeal	
SUBTOTAL (1) (\$)710	121	270	221	135	Request for	r oral hearing		
2 EXTRA CLAIM FEES	138	1,510	138	1,510	Petition to i proceeding	nstitute a public i	ıse	
Fee Extra from Fee	140	110	240	55	Petition to I	revive - unavoida	ble	
Claims below Paid								
Total Claims 20 -20**= 0 x = 0	141	1,240	241	620		revive - unintentio	onal	
Independent 2 - 3**= 0 x = 0	142	1,240	242	620	•	fee (or reissue)		
Claims	143	440	243	220	Design issu			
Multiple Dependent = 0	144	600	244	300	Plant issue		or	ļ
Large Entity Small Entity Fee Fee Fee Fee	122 123	130 50	122 123	130 50		the Commission elated to provisions s		
Code (\$) Code (\$) Fee Description 103 18 203 9 Claims in excess of 20	126	180	126	180	Submissioi Stmt	n of Information [Disclosure	
102 80 202 40 Independent claims in excess of 3	581	40	581	40	Recording	each patent assi mes number of p		
104 270 204 135 Multiple dependent claim, if	146	710	246	355	Filing a sul (37 CFR §	bmission after fin 1.129(a))	al rejection	
not paid 109 80 209 40 **Reissue ındependent claims over original patent	149	710	249	355	For each a	dditional inventio (37 CFR § 1 129	n to be (b))	
110 18 210 9 **Reissue claims in excess of	179	710	279	355	Request for (RCE)	or Continued Exa	mination	
20 and over onginal patent	169	900	169	900		or expedited exam dication	nination of a	
SUBTOTAL (2) (\$)0	Other fee	(specify)						
**or number previously paid, if greater; For Reissues, see above	*Reduced	d by Basio	c Filing Fe	e Paid		SUBTOTAL ((3) (\$)	
					-			
SUBMITTED BY		D:-	tration Al			omplete (If app		705
Name (Print/Type) Irving Newman, Reg. No. 22,638 Registration No. (Attorney/Agent) 22,638 Telephone (908) 231-2785					2785 ∕			

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.